Clindamycin vs Durvalumab

Clindamycin vs Durvalumab: Overview

This comparison examines the pharmacological differences between Clindamycin and Durvalumab.

Mechanism of Action

Clindamycin: Binds 50S ribosomal subunit inhibiting protein synthesis.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Clindamycin — 2-3 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Clindamycin — C18H33ClN2O5S.

Molecular Weight: Clindamycin — 424.9830 g/mol.

Type: Clindamycin — Small molecule; Durvalumab — Antibody.